Table 3.
Molecular Findings in Brenner Tumors, Atypical Proliferative Brenner, and MCA/MBT as Seen in Our Study and Reported in the Literature
| Reference/mutation | Benign Brenner | Atypical proliferative Brenner | MCA/MBT |
|---|---|---|---|
| Current study | MCA/MBT | ||
| KRAS | 0/8 | 1/2 | 4/6 |
| PIK3CA | 0/8 | 1/2 | 1/6 |
| MYC amplification | 3/8 | 2/6 | |
| CDKN2A-HD | NT | NT | NT |
| HRAS | 1/2 | ||
| Kuhn et al6 | |||
| KRAS | 0/20 | 1/7 | |
| PIK3CA | 1/20 | 2/7 | |
| CDKN2A-HD | 0/13 | 7/7 | |
| Cuatrecasas et al7 | |||
| KRAS | 0/5 | 0/5 | |
| PIK3CA | 0/2 | 1/3 | |
| CDKN2A-HD | NT | NT | |
| Hunter et al8 | MCA; MBT | ||
| KRAS | 12/20; 14/22 | ||
| PIK3CA | NT; NT | ||
| CDKN2A-HD | 7/20; 15/22 | ||
| Ryland et al20 | MCA; MBT | ||
| KRAS | 12/22; 18/29 | ||
| PIK3CA | ND; ND | ||
| CDKN2A-HD | 4/22; 12/29 |
CDKN2A-HD, CDKN2A homozygous deletion; MBT, mucinous borderline tumor; MCA, mucinous cystadenoma; ND, not detected; NT, not tested.